Clinical Trial Update: Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating antigen-lipid–driven monoclonal gammopathies targeting epicardial fat has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy
• Obesity
• Overweight

Snippet

Sponsor: University of Miami | Conditions: Monoclonal Gammopathies, Overweight | Phase 4 | Status: WITHDRAWN